<DOC>
	<DOCNO>NCT00396630</DOCNO>
	<brief_summary>The aim study explore horizontal transmission HRV vaccine strain within family twin vaccinate Rotarix twin receive placebo . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>A Study Explore Existence Horizontal Transmission RIX4414 Vaccine Strain Between Twins Within Family .</brief_title>
	<detailed_description>This Phase 3b study . Three dos Infanrix® hexa administer subject discretion investigator . One complimentary dose Rotarix administer infant enrol study ( study group ) age less 6 month Visit 3 ( Week 13 ) benefit placebo group participation study . The study conduct double-blind manner respect Rotarix placebo administer Visit 1 Visit 2 . The parents/guardians subject know within pair twin , one subject receive Rotarix vaccine one subject receive placebo . The study open label respect administration Rotarix vaccine dose give Visit 3 subject group age less 6 month .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects live twin living household also enrol study . Born gestation period ≥32 week , Discharged hospital neonatal care stay , Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include , 6 14 week age time first study vaccination . Healthy subject establish medical history clinical examination enter study . Written inform consent obtain parent guardian subject . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Any clinically significant history chronic gastrointestinal disease . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period . Contact immunosuppressed individual . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration immunosuppressant since birth . Gastroenteritis within 7 day precede first study vaccine administration . Documented HIVpositive subject .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>14 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Transmission</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Shedding</keyword>
	<keyword>rotavirus</keyword>
	<keyword>HRV vaccine</keyword>
</DOC>